FDA granted an Orphan Drug Designation to Cleave Biosciences’ lead drug candidate, CB-5083, for treatment of multiple myeloma.
CB-5083 is a first-in-class, oral inhibitor of p97, an enzyme that controls various aspects of protein homeostasis.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
